SCHEMBL27289110

SCHEMBL27289110

CN1CCC[C@@H](Nc2nnc(-c3ccc(Cl)cc3)c3[nH]ccc23)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 6/20 0.45
▸ NLRP3 Q96P20 6/20 0.45
▸ IL1B P01584 5/20 0.45
▸ CCNT1 O60563 1/20 0.40
▸ CCNK O75909 1/20 0.40
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ CDK12 Q9NYV4 1/20 0.40
▸ MALT1 Q9UDY8 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ TACR2 P21452 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ KMT5B Q4FZB7 1/20 0.38
▸ KMT5C Q86Y97 1/20 0.38
▸ BPTF Q12830 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27289122 0.93 KAT2B (0.46) KAT2BNLRP3IL1BCCNT1CCNK
SCHEMBL27289106 0.90 NLRP3 (0.48) KAT2BNLRP3IL1B
SCHEMBL27290003 0.90 NLRP3 (0.51) KAT2BNLRP3IL1BCCNT1CCNK
SCHEMBL30718315 0.87 IL1B (0.55) KAT2BNLRP3IL1B
SCHEMBL27288792 0.87 IL1B (0.55) KAT2BNLRP3IL1B
SCHEMBL26093063 0.85 KAT2B (0.50) KAT2BNLRP3IL1BCCNT1CCNK
SCHEMBL30374596 0.85 KAT2B (0.50) KAT2BNLRP3IL1BCCNT1CCNK
SCHEMBL26093070 0.85 KAT2B (0.50) KAT2BNLRP3IL1BCCNT1CCNK
SCHEMBL26114790 0.83 NLRP3 (0.60) KAT2BNLRP3IL1BCCNT1CCNK
SCHEMBL26114800 0.83 NLRP3 (0.60) KAT2BNLRP3IL1BCCNT1CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024006559-A1 MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS Neumora Therapeutics, Inc. (US) 2024-01-04 — — WO disclosed
Send feedback